Drugs / C2L-OCT-01 PR
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00642421 | Feb 2008 → Aug 2009 | acromegaly | Ambrilia Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00616551 | Apr 2007 → Feb 2008 | acromegaly | Ambrilia Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C2L-OCT-01 PR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00616551 ↗ |
| Route | Intramuscular | “Administered by deep IM injection (gluteus) on days 1 and 42” NCT00616551 ↗ |